Breaking news

Cyprus Farmers See Lower Input Costs As Producer Prices Rise 5.4% In First Quarter Of 2026

Agricultural input and investment prices in Cyprus fell 2.62% year over year in the first quarter of 2026, while producer prices for agricultural products rose 5.4%, according to data from the state statistical service, Cystat.

The price index for agricultural intermediate consumption and investment stood at 121.37, using 2020 as the base year. Some key costs declined, although farmers continued to face higher prices for machinery, transport equipment and agricultural materials.

Key Input Costs Move In Different Directions

Prices for seeds and planting stock fell 19.4%, the sharpest annual decline among the main input categories. Electricity costs also decreased, dropping 10.95% year over year. Other costs increased. Prices for transport equipment and tractors rose 16.5%, while agricultural materials became 8.23% more expensive.

Producer Prices Rise Across Crops And Livestock

The producer price index for agricultural products reached 134.24, up 5.4% from a year earlier. Crop production led the increase, with its index rising 7.09% to 156.20. Livestock prices also increased, with the sector’s index reaching 124.38, up 4.55% year over year.

Tomatoes And Beef Post The Largest Gains

Tomato prices surged 90% in the first quarter, while apple prices rose 29.5%. Producer prices for seedlings fell 19.4%. Among livestock products, beef recorded the largest increase at 59%. Pork prices declined 15.4%, marking the biggest fall in the category.

Farmers Face Mixed Cost Pressures

Lower prices for seeds, planting stock and electricity could ease some pressure on farmers. Higher machinery, transport equipment and material costs, however, continue to add to production expenses.

At the same time, stronger producer prices for products such as tomatoes and beef could improve returns for producers in those segments.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

Uol
Aretilaw firm
eCredo
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter